Physician profile
Tehming Liang
NPI 1558478487
$6,652.34
in general payments reported to CMS, 2019-2025
27 companies · $1,575 in 2025
The $1,575 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $117 · 2021: $314 · 2022: $1,224 · 2023: $1,100 · 2024: $1,529 · 2025: $1,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,081 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,080.73 |
| Education | $123.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,303.21 | 2019-2025 | |
| Pfizer INC. | $761.11 | 2019-2025 | |
| Janssen Biotech, INC. | $509.53 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $472.74 | 2019-2025 | Ilumya, Winlevi |
| Novartis Pharmaceuticals Corporation | $449.06 | 2019-2025 | |
| Genzyme Corporation | $407.58 | 2019-2025 | |
| Lilly USA, LLC | $390.55 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $373.76 | 2019-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $372.38 | 2019-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $316.90 | 2022-2024 | Vtama |
| Ucb, INC. | $187.17 | 2019-2025 | Bimzelx |
| Incyte Corporation | $181.70 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $178.96 | 2022-2025 | Sotyktu, Zeposia |
| Galderma Laboratories, L.P. | $164.68 | 2019-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $120.88 | 2023-2025 | Zoryve |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $106.17 | 2021-2025 | Anzupgo |
| Organon LLC | $104.84 | 2025 | Vtama |
| Kyowa Kirin, INC. | $53.92 | 2024 | Poteligeo |
| Strata Skin Sciences, INC. | $38.49 | 2022-2024 | Xtrac |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.46 | 2019-2021 | |
| Cipher Pharmaceuticals US LLC | $29.28 | 2025 | Spinosad, Natroba |
| Aclaris Therapeutics, INC. | $20.49 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $18.28 | 2019 | |
| Fresenius Kabi USA, LLC | $16.75 | 2023 | |
| Almirall LLC | $13.26 | 2022 | |
| Nabriva Therapeutics, Plc | $11.79 | 2022 | |
| Biofrontera INC. | $11.40 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tehming Liang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.